Yeo SY - Search Results

1

A positive feedback loop bi-stably activates fibroblasts.

Yeo SY, Lee KW, Shin D, An S, Cho KH, Kim SH. Yeo SY, et al. Nat Commun. 2018 Aug 1;9(1):3016. doi: 10.1038/s41467-018-05274-6. Nat Commun. 2018. PMID: 30069061 Free PMC article.

2

Twist1 is a key regulator of cancer-associated fibroblasts.

Lee KW, Yeo SY, Sung CO, Kim SH. Lee KW, et al. Among authors: yeo sy. Cancer Res. 2015 Jan 1;75(1):73-85. doi: 10.1158/0008-5472.CAN-14-0350. Epub 2014 Nov 3. Cancer Res. 2015. PMID: 25368021

3

PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression.

Lee KW, Yeo SY, Gong JR, Koo OJ, Sohn I, Lee WY, Kim HC, Yun SH, Cho YB, Choi MA, An S, Kim J, Sung CO, Cho KH, Kim SH. Lee KW, et al. Among authors: yeo sy. Nat Commun. 2022 May 19;13(1):2793. doi: 10.1038/s41467-022-30484-4. Nat Commun. 2022. PMID: 35589735 Free PMC article.

4

Twist1 is highly expressed in cancer-associated fibroblasts of esophageal squamous cell carcinoma with a prognostic significance.

Yeo SY, Ha SY, Lee KW, Cui Y, Yang ZT, Xuan YH, Kim SH. Yeo SY, et al. Oncotarget. 2017 May 17;8(39):65265-65280. doi: 10.18632/oncotarget.17941. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029429 Free PMC article.

5

Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis.

Lee HM, Lee E, Yeo SY, Shin S, Park HK, Nam DH, Kim SH. Lee HM, et al. Among authors: yeo sy. Invest New Drugs. 2018 Aug;36(4):545-560. doi: 10.1007/s10637-017-0547-8. Epub 2018 Jan 18. Invest New Drugs. 2018. PMID: 29349597

6

New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts.

Lee E, Yeo SY, Lee KW, Lee JA, Kim KK, Kim SH. Lee E, et al. Among authors: yeo sy. Sci Rep. 2020 Apr 27;10(1):7058. doi: 10.1038/s41598-020-63996-4. Sci Rep. 2020. PMID: 32341496 Free PMC article.

7

Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma.

Ha SY, Yeo SY, Lee KW, Kim SH. Ha SY, et al. Among authors: yeo sy. J Cancer Res Clin Oncol. 2021 Feb;147(2):423-433. doi: 10.1007/s00432-020-03437-x. Epub 2020 Nov 8. J Cancer Res Clin Oncol. 2021. PMID: 33161447

8

The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma.

Ha SY, Yeo SY, Xuan YH, Kim SH. Ha SY, et al. Among authors: yeo sy. PLoS One. 2014 Jun 19;9(6):e99955. doi: 10.1371/journal.pone.0099955. eCollection 2014. PLoS One. 2014. PMID: 24945657 Free PMC article.

9

ZNF282 (Zinc finger protein 282), a novel E2F1 co-activator, promotes esophageal squamous cell carcinoma.

Yeo SY, Ha SY, Yu EJ, Lee KW, Kim JH, Kim SH. Yeo SY, et al. Oncotarget. 2014 Dec 15;5(23):12260-72. doi: 10.18632/oncotarget.2630. Oncotarget. 2014. PMID: 25373738 Free PMC article.

10

Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma.

Yang ZT, Yeo SY, Yin YX, Lin ZH, Lee HM, Xuan YH, Cui Y, Kim SH. Yang ZT, et al. Among authors: yeo sy. PLoS One. 2016 Jan 5;11(1):e0145807. doi: 10.1371/journal.pone.0145807. eCollection 2016. PLoS One. 2016. PMID: 26731558 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters